Change in serum PEDF level after pioglitazone treatment is independently correlated with that in HOMA-IR.
Department of Medicine, Division of Cardio-Vascular Medicine, Kurume University School of Medicine, Kurume, Japan.
Nobuhiro
N
Tahara
Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan.
Takanori
T
Matsui
Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan. Electronic address: shoichi@med.kurume-u.ac.jp.
Sho-Ichi
S
Yamagishi
D000368:Aged; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism*; D005136:Eye Proteins / Q000097:blood*; D005260:Female; D006706:Homeostasis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000097:blood*; D000077205:Pioglitazone; D011446:Prospective Studies; D015843:Serpins / Q000097:blood*; D045162:Thiazolidinediones / Q000627:therapeutic use*; D000099174:Pigment Epithelium-Derived Factor
D005136:Eye Proteins; D007004:Hypoglycemic Agents; D009414:Nerve Growth Factors; D000077205:Pioglitazone; D015843:Serpins; D045162:Thiazolidinediones; D000099174:Pigment Epithelium-Derived Factor
Cardiovascular disease; HOMA-IR; Insulin resistance; PEDF